John Theurer Cancer Center Evaluating Personalized Cancer Vaccine in High-Risk Melanoma

Source: OncLive, March 2020

An ongoing clinical trial will assess whether the adjuvant combination of the personalized cancer vaccine mRNA-4157 and pembrolizumab (Keytruda) improves recurrence-free survival (RFS) compared with pembrolizumab alone in patients with complete resection of cutaneous melanoma and a high-risk of recurrence.1

Seventeen sites are enrolling patients on the multicenter, international trial KEYNOTE-942 trial (NCT03897881), including John Theurer Cancer Center.

“Pembrolizumab and other checkpoint inhibitors have been shown to reduce disease recurrence among patients with high-risk melanoma that was surgically removed. However, in many patients, the cancer eventually comes back,” study investigator Andrew L. Pecora, MD, FACP, CPE, hematologist/oncologist at John Theurer Cancer Center and associate dean, Technology and Innovation, Hackensack Meridian School of Medicine at Seton Hall University, stated in a press release. “Reducing the rate of relapse would address a significant unmet medical need for these patients.”

Read the original full article